Hungary participates in the clinical testing of an anti-COVID drug
Change language:
MSD and Ridgeback Biotherapeutics announced the initiation of Phase 3 MOVe-AHEAD clinical trial to evaluate molnupiravir, an investigational oral antiviral therapeutic, to prevent COVID-19 infection.
The clinical trial is a Phase 3 multicenter, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered molnupiravir compared to placebo in preventing the spread of SARS-CoV-2, Businesswire said.
Molnupiravir is an investigational, orally administered drug that inhibits the replication of multiple RNA viruses, including SARS-CoV-2.
The study will enrol participants at least 18 years old and currently living together with someone who received a positive test for COVID-19, MSD added.
If you are interested, you can enlist HERE.
According to 24, Hungary is also taking a considerable part in the clinical trials, and this will definitely have benefits for the country and the experts who will administer the trial in Hungary.
Hungarian research breakthrough could increase survival time of lung cancer patients
In Hungary, they are currently expecting the participation of 55 volunteers in eight different medical centres. According to Dr Szabolcs BarΓ³tfi, the director of clinical trials at MSD Pharma Hungary Ltd, thanks to the programme, several Hungarian medical professionals will gain the first-hand experience with administering and using the investigational molnupiravir.
He also added that the selection of the participants from the volunteers will start soon and said that the results of the worldwide research are expected to be analysed in the first half of next year.